BioSpace News Archive

Element Biosciences, Inc., developer of the Element AVITI System, an innovative DNA sequencing platform that is disrupting the genomics industry, announced that William ( Bill) P. Donnelly has joined its board of directors.

Sapient Therapeutics Ltd is pleased to announce the successful completion of its Phase 1 Part A comparative trial evaluating the safety and pharmacokinetics of its innovative solid dose prescription cannabidiol (CBD), SAP021.

Vividion Therapeutics, Inc. has been recognized as a Top Workplaces 2023 award winner by the San Diego Union-Tribune for the second year in a row.

Novocure (NASDAQ: NVCR) announced today that management will participate in the 35th Annual Piper Sandler Healthcare Conference on Wednesday, November 29, 2023.

Panavance Therapeutics Inc. announced publication of positive data in the peer-reviewed International Journal of Molecular Sciences in a manuscript titled, “In Vitro Experiments on the Effects of GP-2250 on BRAF-Mutated Melanoma Cell Lines and Benign Melanocytes.”1 The publication by Gambichler, et al.

Revive Therapeutics Ltd. provides an update on the development of a next generation lyophilized formulation of Bucillamine.

Kane Biotech Inc. will announce its third quarter 2023 financial results after market close on Tuesday, November 28, 2023.

Touchlight announced that the Company has used its proprietary dbDNA as a critical starting material for manufacturing of VMB-100, a potency enhanced messenger ribonucleic acid encoding human insulin-like growth factor-1 to support Versameb’s first-in-human clinical study to treat chronic stress urinary incontinence.

ZYUS Life Sciences Corporation is pleased to announce receipt of the final clinical study report and positive results respecting its Phase 1, first-in-human (“FIH”) Clinical Trial for its lead drug product candidate, Trichomylin® softgels.

Alvotech announced today that it will release financial results for the first nine months of 2023, after U.S. markets close on Tuesday, November 28, 2023.